Cargando…

Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study

Excision repair complementary complex 5 (ERCC5) is an important component in the repair pathway of platinum-induced damage. The current study evaluated the effect of ERCC5 variants (rs751402 and rs1047768) on the clinical outcome of platinum-based regimens in non-small cell lung cancer (NSCLC) patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdalkhalek, Esraa S., Wakeel, Lamia M. El, Nagy, Ahmed A., Sabri, Nagwa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296400/ https://www.ncbi.nlm.nih.gov/pubmed/35852645 http://dx.doi.org/10.1007/s12032-022-01741-9

Ejemplares similares

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy
por: Zhang, Ruoxin, et al.
Publicado: (2017)

Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial
por: El-Kady, Rasha R., et al.
Publicado: (2022)

The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
por: Wahba, Nagwa Ismail, et al.
Publicado: (2023)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development
por: Rouissi, Kamel, et al.
Publicado: (2011)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
por: Joo, Jungnam, et al.
Publicado: (2016)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
por: Azambuja, Alan A., et al.
Publicado: (2020)

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
por: Palomba, Grazia, et al.
Publicado: (2014)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe
por: Heyza, Joshua R, et al.
Publicado: (2023)

Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial
por: Sabry, Sarah, et al.
Publicado: (2022)

ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy
por: Qiao, Hongwei, et al.
Publicado: (2014)

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
por: Han, Yali, et al.
Publicado: (2016)

First and Second Line Chemotherapeutic Regimens for Non-Small Cell Lung Carcinomas - The Efficacy of Platinum, Non-Platinum and Combination Therapy: A Literature Review
por: Michael, Anita, et al.
Publicado: (2020)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019)

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2017)

Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure
por: Sarhan, Neven M., et al.
Publicado: (2019)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis
por: Yang, Yanlong, et al.
Publicado: (2014)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Novel ERCC2 variant in trichothiodystrophy infant: the first case report in China
por: Chen, Jian-Dong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9tmlgptkm163qh6nmflc5gmv2r